- Company
- UCB Korea appoints Edward Lee as new GM
- by Son, Hyung Min Nov 13, 2025 06:07am
- UCB Korea announced that Edward Lee has been appointed as its new General Manager, effective November 1. Edward Lee is an expert with over 15 years of experience in the global pharmaceutical industry, in areas ranging from Market Access, Medical Affairs, to Health Economics & Outcomes Research (HEOR). Lee has a strong background in drivin
- Company
- Korea’s bio-industry production hits ₩22.9 trillion
- by Kim, Jin-Gu Nov 12, 2025 06:19am
- Last year, the domestic bio industry's production scale reached KRW 22.9216 trillion, a 9.8% increase compared to the previous year. Exports rose 17.1% year-on-year, driven by existing key export items such as antibody drugs and CMO for biopharmaceuticals. R&D investment increased by 3.2%. The Ministry of Trade, Industry and Energy, in co
- Company
- Biotech firms with net loss overestimate their performance
- by Cha, Jihyun Nov 12, 2025 06:19am
- While Korean biotech and healthcare companies are using the Technology Exception Listing system to challenge the Initial Public Offering (IPO) market, there have been concerns over their valuation methods. Critics argue that some companies are excessively inflating their valuations by presenting overly optimistic estimates of future performance
- Company
- Celltrion completes review for acquiring Lilly pharma plant
- by Choi, Da-eun Nov 12, 2025 06:19am
- Celltrion announced on the 11th that it has completed the merger review process under the Premerger Notification Office (PNO) of the U.S. Federal Trade Commission (FTC) for its acquisition of Eli Lilly's manufacturing facility in Branchburg, New Jersey, USA. This is the final regulatory step, following the merger approval from the Irish gover
- Company
- HanAll, ‘US Immunovant’s HL161 development is on track'
- by Kim, Jin-Gu Nov 12, 2025 06:18am
- HanAll Biopharma’s US partner Immunovant announced the clinical progress of its autoimmune disease treatment candidate ‘HL161’ in a financial report released on November 10 (local time). HL161 is an autoimmune disease treatment candidate developed by Hanall Biopharma. It licensed out the technology to Roivant Sciences, the parent compan
- Company
- Eun Jin Bae appointed Director of Sanofi’s Global MA team
- by Eo, Yun-Ho Nov 11, 2025 06:09am
- Eun-jin Bae (44), MCO Head of Market Access at Sanofi Korea, has been promoted to the global headquarters Market Access team. According to industry sources, Bae, who previously served as MCO Head of Market Access for Korea and the Australia/New Zealand cluster, was officially appointed Director of Sanofi’s Global Market Access team as of
- Company
- Imfinzi nears reimb for biliary tract cancer in Korea
- by Son, Hyung Min Nov 11, 2025 06:09am
- The immunotherapy drug Imfinzi has cleared the Drug Reimbursement Evaluation Committee review and has taken one step closer to expanding reimbursement for biliary tract cancer. Beyond biliary tract cancer, Imfinzi has also shown efficacy in hepatocellular carcinoma and gastric cancer, signaling its potential across the spectrum of gastrointe
- Company
- UCB "Korea is a key country globally…patient access"
- by Hwang, byoung woo Nov 11, 2025 06:08am
- The regulatory strategy of global pharmaceutical companies is changing to enhance access to new drugs in the treatment landscape for rare and intractable diseases. The trend is a 'regulatory science approach' that goes beyond simply meeting approval requirements. It now involves incorporating patient-reported treatment experience and quality
- Company
- Yuhan-Janssen Korea to jointly sell 'Leclaza + Rybrevant'
- by Son, Hyung Min Nov 11, 2025 06:08am
- Johnson & Johnson's Korea-based pharmaceutical unit, Janssen Korea (CEO Chris Rodseth), announced that it will jointly conduct domestic promotion for the non-small cell lung cancer treatment combination therapy, Leclaza (lazertinib) + Rybrevant (amivantamab), with Yuhan Corporation (Yuhan). Previously, promotional activities for the Lec
- Company
- NSCLC standard treatment options undergo major change
- by Son, Hyung Min Nov 11, 2025 06:07am
- The Leclaza + Rybrevant combination therapy has been recommended as the first-line treatment option by the National Comprehensive Cancer Network (NCCN) guidelines, based on its clinical utility. With Tagrisso also listed as a preferred therapy in combination with platinum-based chemotherapy, combination therapy is expected to become the major
